At a glance
ClinicalIndex Comparison RecordN/ACompleted· 92 enrolled
Drug / intervention
CBL-102 eye drops +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye
In Brief
A clinical study evaluating CBL-102 eye drops and Vismed Multi eye drops for Dry Eye. Completed, enrolled 92 participants across 1 site.
Detailed Summary
The primary objectives of this investigation were to show that the performance of CBL-102 Eye Drops is non-inferior to that of Vismed® Multi eye drops in subjects with moderate to severe keratoconjunctivitis sicca after 28 days, and to assess the safety of CBL-102 Eye Drops during a 90-day period with treatment administered 3 to 6 times per day.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesFrance
CollaboratorsBausch & Lomb Incorporated
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedDec 2017
Primary CompletionJun 2020
TodayJul 2026
First PostedDec 11, 2017
Enrollment StartNov 9, 2017
Primary CompletionJun 2, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.6 years ago
Interventions
CBL-102 eye dropsdevice
CBL-102 eye drops, 3 to 6 times per day for 3 months
Vismed Multi eye dropsdevice
Vismed Multi eye drops, 3 to 6 times per day for 3 months